Track Adicet Bio, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Adicet Bio, Inc. ACET · Stock Open Adicet Bio, Inc. in new tab

2.78 USD
EPS
-7.53
P/B
0.20
ROE
-78.08
Beta
1.74
Target Price
29.00 USD
Loading chart...
Key Metrics
Earnings dateMarch 11, 2027
EPS-7.53
Book Value14.83
Price to Book0.20
Debt/Equity10.70
% Insiders6.444%
Estimates
Forward P/E-0.62
Forward EPS-4.82
Target Mean Price29.00

DCF valuation

Model fair value for Adicet Bio, Inc. (ACET)
Result
Sign in to run the valuation for ACET.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus None · mean target 29.00 USD (low 18.00, high 55.00) · as of 10 Nov 2026
Low 18.00
Mean 29.00
High 55.00
Price 2.78
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Adicet Bio, Inc. Logo Adicet Bio, Inc. Analysis (ACET)

United States Health Care Official Website Stock

Is Adicet Bio, Inc. a good investment? Adicet Bio, Inc. (ACET) is currently trading at 2.78 USD. Market analysts have a consensus price target of 29.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Adicet Bio, Inc. is expected to release its next earnings report on March 11, 2027. The market consensus estimate for Forward EPS is -4.82.

Investor FAQ

Does Adicet Bio, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Adicet Bio, Inc.?

Adicet Bio, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 11, 2027. The company currently has a trailing EPS of -7.53.

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Exchange Ticker
LSE (United Kingdom) 0HX7.L
NMS (United States) ACET
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2018
0.00 USD
Oct. 9, 2018 0.0001
June 22, 2018 0.0001
March 23, 2018 0.0006
▸2017
0.00 USD
Dec. 28, 2017 0.0006
Sept. 21, 2017 0.0006
June 23, 2017 0.0006
March 24, 2017 0.0006
▸2016
0.00 USD
Dec. 22, 2016 0.0006
Sept. 20, 2016 0.0006
June 24, 2016 0.0005
March 25, 2016 0.0005
▸2015
0.00 USD
Dec. 28, 2015 0.0005
Oct. 2, 2015 0.0005
June 25, 2015 0.0005
March 26, 2015 0.0005
▸2014
0.00 USD
Dec. 29, 2014 0.0005
Sept. 29, 2014 0.0005
June 27, 2014 0.0005
March 28, 2014 0.0005
▸2013
0.00 USD
Dec. 27, 2013 0.0005
Sept. 27, 2013 0.0005
June 25, 2013 0.0005
March 26, 2013 0.0005
▸2012
0.00 USD
Dec. 28, 2012 0.0005
Sept. 28, 2012 0.0005
June 22, 2012 0.0009
Jan. 18, 2012 0.0009
▸2011
0.00 USD
June 24, 2011 0.0009
Jan. 21, 2011 0.0009
▸2010
0.00 USD
June 25, 2010 0.0009
Jan. 15, 2010 0.0009
▸2009
0.00 USD
June 26, 2009 0.0009
Stock Splits
Split Date Split Ratio to 1
Sept. 16, 2020 0.14
Dec. 30, 2025 0.06
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion